Helene Bonnevaux
R&d
Gent, VLG, Belgium
Gent, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123.
Journal: Nature biotechnology
Published: August 10, 2022
Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment.
Journal: Oncoimmunology
Published: September 06, 2021
SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
Journal: Blood
Published: May 06, 2021
Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
Journal: Molecular cancer therapeutics
Published: June 15, 2015
Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers.
Journal: Journal of medicinal chemistry
Published: January 07, 2014
Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kβ inhibitors.
Journal: Bioorganic & medicinal chemistry letters
Published: June 28, 2012
Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kβ inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers.
Journal: Journal of medicinal chemistry
Published: April 25, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026